SLC22A11 Membrane Protein Introduction

Introduction of SLC22A11

The solute carrier family 22 member 11 (SLC22A11) is a protein encoded by the SLC22A11 gene in humans. It is also known as Organic anion transporter 4 (OAT4). The SLC22A11 has an association with sodium-independent transport and excretion of organic anions, some of which are potentially toxic. The SLC22A11 is mainly expressed in the kidney and placenta, which prevents potentially harmful organic anions from reaching the fetus in the placenta. It is a complete membrane protein.

Basic Information of SLC22A11
Protein Name	Solute carrier family 22 member 11
Gene Name	SLC22A11
Aliases	Organic anion transporter 4 (OAT4)
Organism	Homo sapiens (Human)
UniProt ID	Q9NSA0
Transmembrane Times	12
Length (aa)	550
Sequence	MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTHMLDNGSAVSTNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYDRSVFTSTIVAKWDLVCSSQGLKPLSQSIFMSGILVGSFIWGLLSYRFGRKPMLSWCCLQLAVAGTSTIFAPTFVIYCGLRFVAAFGMAGIFLSSLTLMVEWTTTSRRAVTMTVVGCAFSAGQAALGGLAFALRDWRTLQLAASVPFFAISLISWWLPESARWLIIKGKPDQALQELRKVARINGHKEAKNLTIEVLMSSVKEEVASAKEPRSVLDLFCVPVLRWRSCAMLVVNFSLLISYYGLVFDLQSLGRDIFLLQALFGAVDFLGRATTALLLSFLGRRTIQAGSQAMAGLAILANMLVPQDLQTLRVVFAVLGKGCFGISLTCLTIYKAELFPTPVRMTADGILHTVGRLGAMMGPLILMSRQALPLLPPLLYGVISIASSLVVLFFLPETQGLPLPDTIQDLESQKSTAAQGNRQEAVTVESTSL

Function of SLC22A11 Protein

SLC22A11 is a solute carrier (SLC) family transporter that acts primarily as an organic/dicarboxylic acid exchanger. SLC22A11 is expressed on the basolateral membrane of the syncytia of the placenta and are assumed to be important for the removal of steroid sulfate from the fetal compartment, thereby promoting proper steroid signaling and minimizing toxic effects on developing fetuses. SLC22A11 and SLC22A12 (URAT1) encode a renal urate transporter located on chromosome 11. SLC22A11 is expressed on the apical membrane of renal proximal tubule cells. SLC22A12 is expressed across multiple tissue types and developmental stages, while expression of SLC22A11 is restricted to the kidney and placenta. The solute carrier (SLC) transporter (SLC22A11) is considered to be a model of transport which regulates a variety of abiotic and endogenous organic anions.

Fig.1 The structure of SLC22A11 Protein.

Application of SLC22A11 Protein in Literature

Flynn T.J., et al. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects. Arthritis Research & Therapy. 2013, 15(6): R220. PubMed ID: 24360580.

This analysis supports the fact that there are a number of specific effects on the SLC22A11/SLC22A12 locus that may affect the activity of SLC22A11 and URAT1 and the risk of gout.
Shima J.E., et al. Genetic Variants of Human Organic Anion Transporter 4 Demonstrate Altered Transport of Endogenous Substrates. American Journal of Physiology - Renal Physiology. 2010, 299 (4): F767–F775. PubMed ID: 20668102.

The description of the genetic variation of resorbed transporters such as SLC22A11 is an important step in understanding changes in tubular resorption, which has an important impact on innate steady state processes and drug deployment.
Wang L., Sweet D.H. Interaction of Natural Dietary and Herbal Anionic Compounds and Flavonoids with Human Organic Anion Transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Evidence-based Complementary and Alternative Medicine : eCAM. 2013, (2013):612527. PubMed ID: 23573138.

These data suggest that 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid may lead to important hoat1-mediated DDIs in vivo. Safety issues should be considered in future drug development.
Lofthouse E.M., et al. Glutamate Cycling May Drive Organic Anion Transport on the Basal Membrane of Human Placental Syncytiotrophoblast. The Journal of Physiology. 2015, 593 (20): 4549–4559. PubMed ID: 26277985.

The authors propose that in the fetal blood circulation, glutamate reduces its transmembrane gradient and absorbs the placenta from the fetal circulation, while glutamate reuptake maintains this driving gradient.
Miner J., et al. Lesinurad, a Novel, Oral Compound for Gout, Acts to Decrease Serum Uric Acid through Inhibition of Urate Transporters in the Kidney. Arthritis Research & Therapy. 2016, (18): 214. PubMed ID: 27716403.

The results reveal that the pharmacodynamic and in vitro activities of lesinurad are consistent with the inhibition of URAT1 and SLC22A11.

SLC22A11 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC22A11 antibody development services.

Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: